Sabby Management, LLC Mirati Therapeutics, Inc. Transaction History

Sabby Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $660,050 - $951,450	-5,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $132,130 - $177,450	-1,000 Reduced 16.67%	5,000 $885,000
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $360,000 - $449,325	-2,500 Reduced 29.41%	6,000 $969,000
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $874,059 - $1.22 Million	5,500 Added 183.33%	8,500 $1.46 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $486,150 - $720,810	3,000 New	3,000 $659,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.